Biogen News and Research

RSS
Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Study: Extending natalizumab treatment effective in preventing MS symptoms

Study: Extending natalizumab treatment effective in preventing MS symptoms

UVA researcher identifies potential therapeutic target for myotonic muscular dystrophy

UVA researcher identifies potential therapeutic target for myotonic muscular dystrophy

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis submits second biosimilar candidate MAA to EMA

UIC researchers identify genetic variation that increases MS risk in women

UIC researchers identify genetic variation that increases MS risk in women

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

ALS Association announces research funds to further understand genetic cause of ALS

ALS Association announces research funds to further understand genetic cause of ALS

OPTIMISE project to collect data that provides in-depth picture of MS experiences

OPTIMISE project to collect data that provides in-depth picture of MS experiences

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

Phenotyping human diseases in mice: an interview with Professor Carola Vinuesa

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Living with multiple sclerosis (MS): an interview with Gretchen Rubin and Megan Weigel

Living with multiple sclerosis (MS): an interview with Gretchen Rubin and Megan Weigel

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Pfenex reports total revenue of $3.3 million for second quarter 2014

Pfenex reports total revenue of $3.3 million for second quarter 2014